Cargando…

Stat3 Signaling Pathway: A Future Therapeutic Target for Bone-Related Diseases

Signal transducer and activator of transcription 3 (Stat3) is activated by phosphorylation and translocated to the nucleus to participate in the transcriptional regulation of DNA. Increasing evidences point that aberrant activation or deletion of the Stat3 plays a critical role in a broad range of p...

Descripción completa

Detalles Bibliográficos
Autores principales: Li, Jiadong, Yin, Zhifeng, Huang, Biaotong, Xu, Ke, Su, Jiacan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9081430/
https://www.ncbi.nlm.nih.gov/pubmed/35548357
http://dx.doi.org/10.3389/fphar.2022.897539
_version_ 1784702985923723264
author Li, Jiadong
Yin, Zhifeng
Huang, Biaotong
Xu, Ke
Su, Jiacan
author_facet Li, Jiadong
Yin, Zhifeng
Huang, Biaotong
Xu, Ke
Su, Jiacan
author_sort Li, Jiadong
collection PubMed
description Signal transducer and activator of transcription 3 (Stat3) is activated by phosphorylation and translocated to the nucleus to participate in the transcriptional regulation of DNA. Increasing evidences point that aberrant activation or deletion of the Stat3 plays a critical role in a broad range of pathological processes including immune escape, tumorigenesis, and inflammation. In the bone microenvironment, Stat3 acts as a common downstream response protein for multiple cytokines and is engaged in the modulation of cellular proliferation and intercellular interactions. Stat3 has direct impacts on disease progression by regulating mesenchymal stem cells differentiation, osteoclast activation, macrophage polarization, angiogenesis, and cartilage degradation. Here, we describe the theoretical basis and key roles of Stat3 in different bone-related diseases in combination with in vitro experiments and animal models. Then, we summarize and categorize the drugs that target Stat3, providing potential therapeutic strategies for their use in bone-related diseases. In conclusion, Stat3 could be a future target for bone-related diseases.
format Online
Article
Text
id pubmed-9081430
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-90814302022-05-10 Stat3 Signaling Pathway: A Future Therapeutic Target for Bone-Related Diseases Li, Jiadong Yin, Zhifeng Huang, Biaotong Xu, Ke Su, Jiacan Front Pharmacol Pharmacology Signal transducer and activator of transcription 3 (Stat3) is activated by phosphorylation and translocated to the nucleus to participate in the transcriptional regulation of DNA. Increasing evidences point that aberrant activation or deletion of the Stat3 plays a critical role in a broad range of pathological processes including immune escape, tumorigenesis, and inflammation. In the bone microenvironment, Stat3 acts as a common downstream response protein for multiple cytokines and is engaged in the modulation of cellular proliferation and intercellular interactions. Stat3 has direct impacts on disease progression by regulating mesenchymal stem cells differentiation, osteoclast activation, macrophage polarization, angiogenesis, and cartilage degradation. Here, we describe the theoretical basis and key roles of Stat3 in different bone-related diseases in combination with in vitro experiments and animal models. Then, we summarize and categorize the drugs that target Stat3, providing potential therapeutic strategies for their use in bone-related diseases. In conclusion, Stat3 could be a future target for bone-related diseases. Frontiers Media S.A. 2022-04-25 /pmc/articles/PMC9081430/ /pubmed/35548357 http://dx.doi.org/10.3389/fphar.2022.897539 Text en Copyright © 2022 Li, Yin, Huang, Xu and Su. https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Pharmacology
Li, Jiadong
Yin, Zhifeng
Huang, Biaotong
Xu, Ke
Su, Jiacan
Stat3 Signaling Pathway: A Future Therapeutic Target for Bone-Related Diseases
title Stat3 Signaling Pathway: A Future Therapeutic Target for Bone-Related Diseases
title_full Stat3 Signaling Pathway: A Future Therapeutic Target for Bone-Related Diseases
title_fullStr Stat3 Signaling Pathway: A Future Therapeutic Target for Bone-Related Diseases
title_full_unstemmed Stat3 Signaling Pathway: A Future Therapeutic Target for Bone-Related Diseases
title_short Stat3 Signaling Pathway: A Future Therapeutic Target for Bone-Related Diseases
title_sort stat3 signaling pathway: a future therapeutic target for bone-related diseases
topic Pharmacology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9081430/
https://www.ncbi.nlm.nih.gov/pubmed/35548357
http://dx.doi.org/10.3389/fphar.2022.897539
work_keys_str_mv AT lijiadong stat3signalingpathwayafuturetherapeutictargetforbonerelateddiseases
AT yinzhifeng stat3signalingpathwayafuturetherapeutictargetforbonerelateddiseases
AT huangbiaotong stat3signalingpathwayafuturetherapeutictargetforbonerelateddiseases
AT xuke stat3signalingpathwayafuturetherapeutictargetforbonerelateddiseases
AT sujiacan stat3signalingpathwayafuturetherapeutictargetforbonerelateddiseases